neurology
Multiple sclerosis

In brief: Cost blowout for DMTs; Headache Society ASM for March; Megakaryocytes in the brain

Costs concerns for DMTs in RRMS Fingolimod, ocrelizumab and cladribine constitute 70% of all expenditure on disease-modifying treatment for relapsing-remitting MS in Australia. An analysis of the use and costs of RRMS DMTs found their use increased 27-fold between 1996 and 2019 while annual expenditure increased more than 300-fold from $1.3 million to $437 million. ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic